NanJing Pharmaceutical's return on equity level is worrisome...
NanJing Pharmaceutical's return on equity level is worrisome given its significantly utilized debt. Usually, a high ROE firm without debt is seen as superior. Between two firms with analogous debt-to-equity, the preference is for the higher ROE.
What NanJing Pharmaceutical Company Limited's (SHSE:600713) ROE Can Tell Us
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment